Atezolizumab Combo Results in Intracranial Activity in BRAFV600+ Melanoma
Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.
FDA Places Partial Clinical Hold on Phase 1 Trial of Davoceticept Pembrolizumab in Advanced Malignancies
A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.
Cosibelimab Being Evaluated for Metastatic cSCC
The anti–PD-L1, fully human monoclonal antibody cosibelimab will be examined in a cohort of patients with metastatic cutaneous squamous cell carcinoma (cSCC) as part of an ongoing phase 1 study.
2 Clarke Drive Cranbury, NJ 08512